Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Cerebral Palsy Improves After Bone Marrow Stem Cell Procedure
Dr. David Steenblock of Mission Viejo, California, a pioneer in clinical applications of stem cells, is pleased to report the results of a 16 year old girl who suffered from cerebral palsy. The patient had right side paralysis and spasticity since birth. The procedure consisted of removing 300 milliliters of bone marrow from her hip and giving it back to her intravenously. Five hours after the raw bone marrow infusion, E.H. was able to move her right toe for the first time in her life. That evening, she was able to walk, stepping heel to toe on her right foot. By the next day, she was able to straighten out and use her right arm and wrist for the first time. Within three weeks, she was also able to move her fingers on her right hand and hold a cup for the first time.

CSIRO Deal To Commercialize 'Artificial Gut'
CSIRO Food Futures National Research Flagship and Australian company Stadvis Pty Ltd have signed a worldwide license agreement to commercialise an automated instrument that accurately predicts glycemic index (GI) and resistant starch (RS) in food products.
News of the day
Senesco Announces H1N1 Influenza Survival Test Results In Mice
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) reported results of H1N1 mouse influenza survival studies that were conducted in Dr. William Scheld"s lab at the University of Virginia School of Medicine. Mice treated with an siRNA against Senesco"s Factor 5A gene had a 52% survival rate as opposed to a 14% survival rate for mice that received no treatment or a control siRNA.
Diagnostics

Candela Receives Registration Approval To Market The Alex TriVantage Laser In Brazil

Candela Corporation (NASDAQ:CLZR) announced that it has received registration approval from the Brazilian National Health Surveillance Agency (ANVISA) to market the Candela Alex TriVantage® multi-wavelength, q-switched laser system in Brazil. "Until now, providing high quality and effective treatment for pigmented lesions and multi-color tattoos meant that Brazilian doctors needed to own at least two different lasers. With Alex TriVantage"s Laser-Pumped-Laser (LPL) technology, a greater number of doctors will be able to offer a wider variety of services assured of the ability to provide treatment regardless of the patient"s skin color," said Candela President and Chief Executive Officer, Gerard E. Puorro. "This approval increases the number of Candela products marketed in Brazil, enabling us to offer a more complete range of highly effective aesthetic laser solutions." Unique, q-switched Laser-Pumped-Laser (LPL) technology provides 755 nm, 532 nm and 1064 nm output wavelengths, making Alex TriVantage extremely versatile. The addition of a long-pulse mode at 755nm offers advanced treatments for a wider variety of pigmented lesions without side effects. Beyond the treatment of benign pigmented lesions and the removal of multi-color tattoo inks, Alex TriVantage enhances the results of many skin rejuvenation treatments, making it an ideal system for optimizing fractional and other rejuvenation treatment results. The Alex TriVantage platform has received wide acclaim including a recent feature on ABC"s nationally broadcasted "The View". To see dermatologist Suzanne Kilmer, MD from Sacramento, CA performing a tattoo removal treatment, visit Candela"s website at http://www.candelalaser.com/theview. Candela Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009